Related references
Note: Only part of the references are listed.COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
Maria Pia Sormani et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
Adherence to Therapy in Patients with Multiple Sclerosis-Review
Aleksandra Koltuniuk et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
Smouldering multiple sclerosis: the 'real MS'
Gavin Giovannoni et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2022)
An updated review of teriflunomide's use in multiple sclerosis
Aaron E. Miller
NEURODEGENERATIVE DISEASE MANAGEMENT (2021)
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria P. Sormani et al.
ANNALS OF NEUROLOGY (2021)
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study
Sebastiano Bucello et al.
JOURNAL OF NEUROLOGY (2021)
Teriflunomide: Pediatric First Approval
Julia Paik
PEDIATRIC DRUGS (2021)
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study
Giorgia T. Maniscalco et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
COVID-19 in teriflunomide-treated patients with multiple sclerosis
Amir Hadi Maghzi et al.
JOURNAL OF NEUROLOGY (2020)
Silent progression in disease activity-free relapsing multiple sclerosis
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2019)
Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis
Robert Zivadinov et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Towards personalized therapy for multiple sclerosis: limitations of observational data
Ewout W. Steyerberg et al.
BRAIN (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
Stefan Braune et al.
JOURNAL OF NEUROLOGY (2018)
No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study
Patricia K. Coyle et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman et al.
FRONTIERS IN NEUROLOGY (2017)
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study
Emanuele D'Amico et al.
JOURNAL OF NEUROLOGY (2016)
Optimizing therapy early in multiple sclerosis: An evidence-based view
Tjalf Ziemssen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Influence of treatments in multiple sclerosis disability: A cohort study
Eleonora Cocco et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Amit Bar-Or et al.
DRUGS (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
Maria Trojano et al.
PLOS ONE (2012)